Value of plasma levels of cardiac myosin-binding protein C as a diagnostic and prognostic biomarker in heart failure

Objective To study the value of measuring plasma levels of cardiac myosin-binding protein C (cMyBP-C) as a biomarker in the diagnosis and prognosis of heart failure (HF) in pediatric patients. Background Previous research studies have declared that cMyBP-C phosphorylation modulates cardiac contractility. It is a thick filament-associated protein which regulates actin–myosin interaction and thereby the systolic and diastolic function of the heart and regulates cardiac contractility. CMyBP-C has been reported in many studies as a specific early diagnostic biomarker of myocardial infarction. Patients and methods To reach the goal of this research, a case–control study was designed. The study sample included 35 Egyptian children from the hospitalized children at Menoufia University Hospital with HF as 'a patient group' and 30 apparently healthy children of similar age and sex matched as 'a control group.' Results We found a significant increase in cMyBP-C (P = 0.001) in the patients with HF. There was a statistically significant difference between cMyBP-C in the patients at admission and their ROSS classification, as higher level was noticed in class IV in relation to classes II and III (P = 0.001), and also higher in class III in relation to class II (P = 0.0.008). Conclusion Our study reveals that the plasma level of cMyBP-C is a significant biomarker, which can be used for diagnosis and prognosis of HF in pediatric patients.